Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review

Ana Iglesias; Raluca Oancea; Carmen Cotarelo; Eduardo Anguita

doi:10.3892/br.2021.1459

Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review

Biomedical Reports ◽

10.3892/br.2021.1459 ◽

2021 ◽

Vol 15 (4) ◽

Author(s):

Ana Iglesias ◽

Raluca Oancea ◽

Carmen Cotarelo ◽

Eduardo Anguita

Keyword(s):

Case Report ◽

Literature Review ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors

Download Full-text

Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review on Toxicity Profiles

Archives in Cancer Research ◽

10.21767/2254-6081.1000139 ◽

2017 ◽

Vol 05 (02) ◽

Author(s):

Aileen Deng ◽

Andrew Chapman ◽

Jianqing Lin

Keyword(s):

Case Report ◽

Literature Review ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

The Elderly

Download Full-text

TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)

Oncohematology ◽

10.17650/1818-8346-2017-12-3-41-49 ◽

2017 ◽

Vol 12 (3) ◽

pp. 41-49

Author(s):

K. I. Zarubina ◽

E. N. Parovichnikova ◽

O. A. Gavrilina ◽

A. N. Sokolov ◽

V. V. Troitskaya ◽

...

Keyword(s):

Case Report ◽

Acute Lymphoblastic Leukemia ◽

Literature Review ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Lymphoblastic Leukemia

Download Full-text

Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review

Clinical Lung Cancer ◽

10.1016/j.cllc.2014.11.001 ◽

2015 ◽

Vol 16 (2) ◽

pp. e5-e9 ◽

Cited By ~ 14

Author(s):

Ning Zhao ◽

Shu-yi Zheng ◽

Jin-ji Yang ◽

Xu-chao Zhang ◽

Zhi Xie ◽

...

Keyword(s):

Case Report ◽

Literature Review ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Egfr Mutation

Download Full-text

Review for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

10.1002/hon.2721/v1/review1 ◽

2019 ◽

Author(s):

Mark Heaney

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Philadelphia Chromosome Positive

Download Full-text

Decision letter for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"

10.1002/hon.2721/v1/decision1 ◽

2019 ◽

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors ◽

Philadelphia Chromosome ◽

Philadelphia Chromosome Positive

Download Full-text

Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis

Cancer Treatment and Research Communications ◽

10.1016/j.ctarc.2021.100407 ◽

2021 ◽

pp. 100407

Author(s):

Rafael Rubiera-Pebe ◽

James K. Hicks ◽

Tawee Tanvetyanon

Keyword(s):

Lung Cancer ◽

Case Report ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Pooled Analysis

Download Full-text

Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

Annals of Hematology ◽

10.1007/s00277-021-04406-1 ◽

2021 ◽

Author(s):

Massimo Breccia ◽

◽

Simone Celant ◽

Pier Paolo Olimpieri ◽

Odoardo M. Olimpieri ◽

...

Keyword(s):

Chronic Myeloid Leukemia ◽

Mortality Rate ◽

Tyrosine Kinase ◽

Retrospective Analysis ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Second Generation ◽

Kinase Inhibitors ◽

Chronic Phase

Download Full-text

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

British Journal of Haematology ◽

10.1111/j.1365-2141.2010.08245.x ◽

2010 ◽

Vol 150 (3) ◽

pp. 303-312 ◽

Cited By ~ 24

Author(s):

Fabio P. S. Santos ◽

Hagop Kantarjian ◽

Carmen Fava ◽

Susan O’Brien ◽

Guillermo Garcia-Manero ◽

...

Keyword(s):

Chronic Myeloid Leukaemia ◽

Tyrosine Kinase ◽

Myeloid Leukaemia ◽

Tyrosine Kinase Inhibitors ◽

Second Generation ◽

Kinase Inhibitors ◽

Clinical Impact ◽

Dose Reductions

Download Full-text

Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?

Seminars in Hematology ◽

10.1053/j.seminhematol.2010.06.002 ◽

2010 ◽

Vol 47 (4) ◽

pp. 344-353 ◽

Cited By ~ 8

Author(s):

Elias Jabbour ◽

Hagop Kantarjian ◽

Jorge Cortes

Keyword(s):

Chronic Myeloid Leukemia ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Myeloid Leukemia ◽

Second Generation ◽

Kinase Inhibitors

Download Full-text

Second-Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status

Renal Cell Carcinoma ◽

10.1007/978-1-4939-1622-1_9 ◽

2014 ◽

pp. 207-216

Author(s):

Linda Cerbone ◽

Cora N. Sternberg

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Tyrosine Kinase Inhibitors ◽

Renal Cell ◽

Second Generation ◽

Kinase Inhibitors ◽

Current Status

Download Full-text